Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion-February 2024-www.financetom.com

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

Sep 22, 2025 4:20 AM

(Reuters) -Pfizer ( PFE ) said on Monday it would acquire weight-loss drug developer Metsera ( MTSR ) for up to $4.9 billion to secure its position in the lucrative obesity treatment market.

Previous page： Once a beacon of stability, Vietnam to name third president in a year Next page： Japan's union group Rengo announces biggest wage hikes on record

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Once a beacon of stability, Vietnam to name third president in a year

Mar 22, 2024

HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...

Japan's union group Rengo announces biggest wage hikes on record

Mar 22, 2024

TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...

Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut

Mar 22, 2024

Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug

Mar 22, 2024

05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...